New ISPE Good Practice Guide: Decommissioning of Pharmaceutical Equipment and Facilities Is the Essential Toolbox to Aid in the Decommissioning Process
ISPE announced the release of their latest guidance document, ISPE Good Practice Guide: Decommissioning of Pharmaceutical Equipment and Facilities. This guide provides an overview of best practices to be used for the decommissioning and disposal of assets ranging from a single item to a whole facility.
“The guide also brings together a wealth of information and sample documents that can significantly aid in the decommissioning process,” said Nick Haycocks, Senior Specialist QA, Amgen Inc. “It’s truly a one-stop-shop for information, featuring checklists, templates, and flowcharts currently used in the US and Europe,” added Mark Foss, Central Engineering and Facilities Director, UK Manufacturing, CooperVision.
The ISPE Good Practice Guide: Decommissioning of Pharmaceutical Equipment and Facilities describes a risk-based approach for planning and documenting the decommissioning process to meet the requirements of regulatory authorities. This guide also provides examples and sample documents for how this approach can be carried out in practice.
Key Concepts include:
• Guidance on decommissioning
• The use of a decommissioning determination process
• Planning for Good Engineering Practice (GEP) and GxP systems
The Good Practice Guide is a collection of the practical advice and experience from a wide range of personnel in the life sciences industry. The contributors of this guide have a great deal of experience through site closures, equipment decommissioning, and product/equipment transfers.
Get your copy today of the newly released ISPE Good Practice Guide: Decommissioning of Pharmaceutical Equipment and Facilities.
The following blog post was provided by Peyton Myers, an undergraduate student at Appalachian State University. Myers attended the 2023 ISPE Annual Meeting & Expo in Las Vegas as an ISPE Foundation Professional Development Grant recipient.
The integration of data science in biopharmaceutical manufacturing, emphasizing data quality, tech transfer efficiency, and process optimization, is the heart of this track. Led by industry experts, discussions explore leveraging digital twins, predictive analytics, and continuous improvement initiatives. Additionally, interactive roundtable discussions provide attendees with a dynamic forum...
The pharmaceutical sector stands at a crossroads of immense possibilities. We are witnessing an unprecedented surge in innovation, fueled by a remarkable partnership between industry and regulatory authorities. For example, there are initiatives fostered by the US Food and Drug Administration (US FDA) to promote innovation with programs such as CATT (CBER Advanced Technologies Team) and ETP...
